NasdaqGS:IMGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.3b

Last Updated

2021/06/20 17:00 UTC

Data Sources

Company Financials +

Executive Summary

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has ImmunoGen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: IMGN's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

3.2%

IMGN

-3.2%

US Biotechs

-1.9%

US Market


1 Year Return

54.9%

IMGN

18.9%

US Biotechs

38.2%

US Market

Return vs Industry: IMGN exceeded the US Biotechs industry which returned 18.9% over the past year.

Return vs Market: IMGN exceeded the US Market which returned 38.2% over the past year.


Shareholder returns

IMGNIndustryMarket
7 Day3.2%-3.2%-1.9%
30 Day4.2%2.6%1.1%
90 Day-22.9%1.6%4.3%
1 Year54.9%54.9%20.6%18.9%40.4%38.2%
3 Year-44.9%-44.9%9.2%4.7%57.5%47.8%
5 Year113.7%113.7%60.4%47.8%127.2%101.7%

Long-Term Price Volatility Vs. Market

How volatile is ImmunoGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ImmunoGen undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IMGN ($6.69) is trading below our estimate of fair value ($23.56)

Significantly Below Fair Value: IMGN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IMGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IMGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMGN is overvalued based on its PB Ratio (14.2x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is ImmunoGen forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

57.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMGN's revenue (50.5% per year) is forecast to grow faster than the US market (9.5% per year).

High Growth Revenue: IMGN's revenue (50.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMGN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ImmunoGen performed over the past 5 years?

12.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMGN is currently unprofitable.

Growing Profit Margin: IMGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMGN is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.

Accelerating Growth: Unable to compare IMGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: IMGN has a negative Return on Equity (-52.42%), as it is currently unprofitable.


Financial Health

How is ImmunoGen's financial position?


Financial Position Analysis

Short Term Liabilities: IMGN's short term assets ($319.6M) exceed its short term liabilities ($134.4M).

Long Term Liabilities: IMGN's short term assets ($319.6M) exceed its long term liabilities ($117.5M).


Debt to Equity History and Analysis

Debt Level: IMGN's debt to equity ratio (2.2%) is considered satisfactory.

Reducing Debt: IMGN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMGN has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 3.2% each year.


Dividend

What is ImmunoGen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Mark Enyedy (56 yo)

5.08yrs

Tenure

US$4,600,626

Compensation

Mr. Mark Joseph Enyedy is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and served as its Interim Pr...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD4.60M) is about average for companies of similar size in the US market ($USD3.73M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IMGN's management team is not considered experienced ( 2 years average tenure), which suggests a new team.


Board Members

Experienced Board: IMGN's board of directors are considered experienced (9.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.


Top Shareholders

Company Information

ImmunoGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImmunoGen, Inc.
  • Ticker: IMGN
  • Exchange: NasdaqGS
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.338b
  • Shares outstanding: 199.94m
  • Website: https://www.immunogen.com

Number of Employees


Location

  • ImmunoGen, Inc.
  • 830 Winter Street
  • Waltham
  • Massachusetts
  • 02451-1477
  • United States

Listings


Biography

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/20 17:00
End of Day Share Price2021/06/18 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.